Want to see ALMS full AI Analyst Report?
ALMS Stock Chart & Stats
$24.99
-$0.47(-5.84%)
At close: 4:00 PM EST
$24.99
-$0.47(-5.84%)
Day’s Range― - ―
52-Week Range$3.75 - $31.35
Previous CloseN/A
Volume29.29K
Average Volume (3M)1.60M
Market Cap
$3.57B
Enterprise Value$2.82B
Total Cash (Recent Filing)$522.94M
Total Debt (Recent Filing)$35.66M
Price to Earnings (P/E)―
Beta-1.27
Next Earnings
Aug 19, 2026EPS Estimate
-0.72Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.91
Shares Outstanding123,432,076
10 Day Avg. Volume1,092,853
30 Day Avg. Volume1,597,276
Financial Highlights & Ratios
PEG Ratio0.05
Price to Book (P/B)27.54
Price to Sales (P/S)345.07
P/FCF Ratio-22.42
Enterprise Value/Market Cap0.79
Enterprise Value/Revenue335.26
Enterprise Value/Gross Profit374.04
Enterprise Value/Ebitda-6.80
Forecast
1Y Price Target
$40.00Price Target Upside60.06% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering8
EPS Forecast (FY)-2.86
Revenue Forecast (FY)$7.82M
Bulls Say, Bears Say
Bulls Say
Low Leverage / Strong CapitalizationAlumis’ minimal debt relative to equity (debt-to-equity ~0.06) is a durable financial strength: it reduces near-term refinancing risk, preserves flexibility to fund R&D or acquisitions, and provides a stronger buffer against cash burn while management executes clinical milestones.
High Gross Margins / Favorable Unit EconomicsSustained high gross margins indicate attractive unit economics for Alumis’ small-molecule assets. If and when products reach commercialization, these margins support scalable profitability. Durable margin advantage helps the company leverage future revenue with less incremental cost.
Clinically Validated TYK2 Pipeline With Phase 3 SuccessPositive Phase 3 psoriasis data and a clear TYK2 strategy materially reduce development risk and strengthen competitive positioning in a multibillion-dollar immunology market. Ongoing milestone cadence and breadth across indications create durable optionality for future approvals and revenue streams.
Bears Say
Heavy Operating Cash BurnSustained negative operating and free cash flow at scale (-~$376M TTM) is a structural strain: it shortens runway, forces frequent capital raises or dilution, and can limit ability to fund pivotal trials or commercial launch without external financing over the next 2–6 months.
Sharp, Declining Revenue BaseA very small and falling revenue base (≈$8.4M, -65% TTM) signals lack of sustainable commercial cash flow. This structural weakness heightens dependence on financing and milestone receipts, increasing execution risk until meaningful product revenues are achieved.
Large Operating Losses And Negative Returns On EquityChronic large operating losses and strongly negative ROE indicate the company is eroding economic value. Over time this can diminish investor capital, constrain strategic options, and necessitate dilutive funding or asset sales if clinical progress does not translate into near-term monetization.
Alumis Inc. News
ALMS FAQ
What was Alumis Inc.’s price range in the past 12 months?
Alumis Inc. lowest stock price was $3.75 and its highest was $31.35 in the past 12 months.
What is Alumis Inc.’s market cap?
Alumis Inc.’s market cap is $3.57B.
When is Alumis Inc.’s upcoming earnings report date?
Alumis Inc.’s upcoming earnings report date is Aug 19, 2026 which is in 24 days.
How were Alumis Inc.’s earnings last quarter?
Alumis Inc. released its earnings results on May 14, 2026. The company reported -$0.74 earnings per share for the quarter, beating the consensus estimate of -$0.743 by $0.003.
Is Alumis Inc. overvalued?
According to Wall Street analysts Alumis Inc.’s price is currently Undervalued.
Does Alumis Inc. pay dividends?
Alumis Inc. does not currently pay dividends.
What is Alumis Inc.’s EPS estimate?
Alumis Inc.’s EPS estimate is -0.72.
How many shares outstanding does Alumis Inc. have?
Alumis Inc. has 123,432,076 shares outstanding.
What happened to Alumis Inc.’s price movement after its last earnings report?
Alumis Inc. reported an EPS of -$0.74 in its last earnings report, beating expectations of -$0.743. Following the earnings report the stock price went down -7.146%.
Which hedge fund is a major shareholder of Alumis Inc.?
Currently, no hedge funds are holding shares in ALMS
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Alumis Inc. Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$40.00 (60.06% Upside)
$40.00 (60.06% Upside)
Blogger Sentiment
Bullish
ALMS Sentiment 70%
Sector Average 65%
Sector Average 65%
Hedge Fund Trend
Increased
By 294.1K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $140.0K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 2.2%
Last 30 Days ▼ 4.4%
Last 30 Days ▼ 4.4%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
636.97%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
157.02%
Trailing 12-Months
Company Description
Alumis Inc.
Alumis Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of medicines for autoimmune disorders. The company offers envudeucitinib, a tyrosine kinase 2 (TYK2) inhibitor for the treatment of plaque psoriasis and systemic lupus erythematosus; and A-005, a central nervous system-penetrant allosteric TYK2 inhibitor that is in Phase 1 for the treatment of neuroinflammatory and neurodegenerative diseases. It also develops lonigutamab, a monoclonal antibody targeting IGF-1R for the treatment of thyroid eye diseases; and interferon regulatory factor 5 (IRF5) to address immune dysfunction. The company was formerly known as Esker Therapeutics, Inc. and changed its name to Alumis Inc. in January 2022. Alumis Inc. was incorporated in 2021 and is headquartered in South San Francisco, California.
ALMS Stock 12 Month Forecast
Average Price Target
$40.00
▲(60.06% Upside)
Technical Analysis
Ownership Overview
43.97% Insiders
9.45% Mutual Funds
0.37% Other Institutional Investors
36.62% Public Companies and
Individual Investors